Enzalutamide, an inhibitor of androgen receptor (AR) function, is a popular drug commonly prescribed to treat advanced prostate cancer, but resistant prostate cancer eventually develops which grow aggressively, leading to widespread metastatic disease and ends up with a lethal outcome (1, 2, 3). This evidence concerns the gene AR and prostate carcinoma.